Patrick Rossignol is a nephrologist and vascular medicine specialist, European Society of Hypertension-certified hypertension specialist and Professor of Therapeutics at the University of Lorraine, France.

Since 2018, he has been Director of the Nancy University Hospital INSERM Clinical Investigation Centre, after serving as its Deputy Director for ten years.
Since 2014, he has been coordinating a French multidisciplinary (basic researchers, cardiologists, nephrologists, intensivists, epidemiologists, geriatricians) network of excellence endorsed by the French affiliate of ECRIN/ERIC: Cardiovascular and Renal Clinical Trialists (INI-CRCT). He is a researcher at the French National Institute of Health and Medical Research (INSERM U1116), runs outpatient clinics at the University Hospital Heart Failure and Hypertension Unit (ESH excellence centre), as well as in a haemodialysis clinic within a disease management programme (ALTIR).

He is involved in translational basic research studies on the mechanisms of transition of hypertension and metabolic disorders to the cardiorenal syndrome in heart failure. He has been participating in four EU FP programmes across the heart failure spectrum and has been a EURECA-m (cardiorenal working group of ERAEDTA) member since its creation in 2009. He is mainly involved in clinical trials in the settings of heart failure, hypertension and chronic kidney disease.

He is the Principal Investigator of the ongoing academic (PHRCN) placebo-controlled, cardiovascular outcome, randomised clinical trial in haemodialysis (ALCHEMIST: spironolactone vs. placebo NCT01848639) and of the randomised clinical trial of carotid barostimulation in resistant hypertension (PRME ESTIM rHTN: NCT02364310) and is steering committee member of several international randomised clinical trials, DSMC chair of two national trials funded by the French Ministry of Health and finally Chair of the Critical Event Committee of an international trial.

Since 2016, he has been serving as a board member in the cardiorenal dysfunction and translational committees of the Heart Failure Association of the European Society of Cardiology. He is the Kidney Disease Clinical Trialists think-tank course director, gathering academic and industry KOLs, FDA/EMA members, patients and payers.

He has published more than 250 peer-reviewed publications (Google scholar H-index = 46,39 since 2014) and is co-inventor of 8 biomarker international patents in the cardiorenal syndrome setting. He is one of the CardioRenal cofounders.